128 related articles for article (PubMed ID: 7769275)
1. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
[TBL] [Abstract][Full Text] [Related]
3. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
[TBL] [Abstract][Full Text] [Related]
4. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals.
Mutch D; Underwood J; Geysen M; Rodda S
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):879-90. PubMed ID: 7519672
[TBL] [Abstract][Full Text] [Related]
6. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
7. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
8. Surface expression of the HIV-1 envelope proteins in env gene-transfected CD4-positive human T cell clones: characterization and killing by an antibody-dependent cellular cytotoxic mechanism.
Ahmad A; Yao XA; Tanner JE; Cohen E; Menezes J
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):789-98. PubMed ID: 7912729
[TBL] [Abstract][Full Text] [Related]
9. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
[TBL] [Abstract][Full Text] [Related]
10. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
11. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
Zaghouani H; Hall B; Shah H; Bona C
Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
[No Abstract] [Full Text] [Related]
13. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HIV-1 envelope-specific CD4+ T cell lines simultaneously established from peripheral blood mononuclear cells and lymph node biopsy in HIV-1-infected individuals.
Ratto-Kim S; Sitz KV; Scherer AM; Kim JH; Anderson DW; Nau ME; Mann DL; Akolkar PN; Gulwani-Akolkar B; Silver J; Birx DL
J Immunol; 1997 Nov; 159(10):5162-7. PubMed ID: 9366447
[TBL] [Abstract][Full Text] [Related]
15. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
Orentas RJ; Hildreth JE; Obah E; Polydefkis M; Smith GE; Clements ML; Siliciano RF
Science; 1990 Jun; 248(4960):1234-7. PubMed ID: 2190315
[TBL] [Abstract][Full Text] [Related]
16. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals.
Clerici M; Lucey DR; Zajac RA; Boswell RN; Gebel HM; Takahashi H; Berzofsky JA; Shearer GM
J Immunol; 1991 Apr; 146(7):2214-9. PubMed ID: 1826020
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Kundu SK; Katzenstein D; Moses LE; Merigan TC
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 neutralizing antibodies in urine from seropositive individuals.
Cao YZ; Friedman-Kien AE; Mirabile M; Li XL; Alam M; Dieterich D; Ho DD
J Acquir Immune Defic Syndr (1988); 1990; 3(3):195-9. PubMed ID: 1968094
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase.
Lieberman J; Fabry JA; Kuo MC; Earl P; Moss B; Skolnik PR
J Immunol; 1992 May; 148(9):2738-47. PubMed ID: 1374097
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
